Correlation of low expression of hMOF with clinicopathological features of colorectal carcinoma, gastric cancer and renal cell carcinoma

International Journal of Oncology

Volumn 44, Issue 4, 2014, Pages 1207-1214

  Cao, Lingling ^a   Zhu, Lin ^a   Yang, Jiaxing ^b   Su, Jiaming ^a   Ni, Jinsong ^b   Du, Yujun ^b   Liu, Da ^a   Wang, Yanfang ^b   Wang, Fei ^a   Jin, Jingji ^a   Cai, Yong ^a  

^a JILIN UNIVERSITY   (China)

^b THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

Author keywords

Colorectal cancer; Gastric cancer; hMOF; Renal cell carcinoma

Indexed keywords

HISTONE; HISTONE ACETYLTRANSFERASE; KAT8 PROTEIN, HUMAN; TUMOR MARKER;

ACETYLATION; AGED; BIOSYNTHESIS; COLORECTAL TUMOR; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETICS; HUMAN; KIDNEY CARCINOMA; LYMPH NODE METASTASIS; MALE; METABOLISM; MORTALITY; PATHOLOGY; STOMACH TUMOR;

ACETYLATION; AGED; CARCINOMA, RENAL CELL; COLORECTAL NEOPLASMS; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE ACETYLTRANSFERASES; HISTONES; HUMANS; LYMPHATIC METASTASIS; MALE; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84894441506     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2266     Document Type: Article

References (34)

1. Jin J, Cai Y, Li B, Conaway RC, Workman JL, Conaway JW and Kusch T: In and out: histone variant exchange in chromatin. Trends Biochem Sci 30: 680-687, 2005.
2. Waldmann T and Schneider R: Targeting histone modifications - epigenetics in cancer. Curr Opin Cell Biol 25: 184-189, 2013.
3. Sharma S, Kelly TK and Jones PA: Epigenetics in cancer. Carcinogenesis 31: 27-36, 2010.
4. Bannister AJ and Kouzarides T: Regulation of chromatin by histone modifications. Cell Res 21: 381-395, 2011.
5. Hatzimichael E and Crook T: Cancer epigenetics: new therapies and new challenges. J Drug Deliv 2013: 529312, 2013.
6. Haberland M, Montgomery RL and Olson EN: The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet 10: 32-42, 2009.
7. Shi Y: Histone lysine demethylases: emerging roles in development, physiology and disease. Nat Rev Genet 8: 829-833, 2007.
8. Feinberg AP, Ohlsson R and Henikoff S: The epigenetic progenitor origin of human cancer. Nat Rev Genet 7: 21-33, 2006.
9. Jones PA and Martienssen R: A blueprint for a human epigenome project: the AACR human epigenome workshop. Cancer Res 65: 11241-11246, 2005.
10. Fraga MF, Ballestar E, Villar-Garea A, et al: Loss of acetylation at Lys 16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 37: 391-400, 2005.
11. Elsheikh SE, Green AR, Rakha EA, et al: Global histone modifications in breast cancer correlate with tumor phenotypes, prognostic factors, and patient outcome. Cancer Res 69: 3802-3809, 2009.
12. Barlesi F, Giaccone G, Gallegos-Ruiz MI, et al: Global histone modifications predict prognosis of resected non small-cell lung cancer. J Clin Oncol 25: 4358-4364, 2007.
13. Mosashvilli D, Kahl P, Mertens C, et al: Global histone acetylation levels: prognostic relevance in patients with renal cell carcinoma. Cancer Sci 101: 2664-2669, 2010.
14. Sharma GG, So S, Gupta A, et al: MOF and histone H4 acetylation at lysine 16 are critical for DNA damage response and double-strand break repair. Mol Cell Biol 30: 3582-3595, 2010.
15. Carrozza MJ, Utley RT, Workman JL and Côté J: The divers functions of histone acetyltransferase complexes. Trends Genet 19: 321-329, 2003.
16. Gupta A, Guerin-Peyrou TG, Sharma GG, et al: The mammalian ortholog of Drosophla MOF that acetylates histone H4 lysine 16 is essential for embryogenesis and oncogenesis. Mol Cell Biol 28: 397-409, 2008.
17. Smith ER, Cayrou C, Huang R, Lane WS, Côté J and Lucchesi JC: A human protein complex homologous to the Drosophila MSL complex is responsible for the majority of histone H4 acetylation at lysine 16. Mol Cell Biol 25: 9175-9188, 2005.
18. Cai Y, Jin J, Swanson SK, et al: Subunit composition and substrate specificity of a MOF-containing histone acetyltransferase distinct from the male-specific lethal (MSL) complex. J Biol Chem 285: 4268-4272, 2010.
19. Mendjan S, Taipale M, Kind J, et al: Nuclear pore components are involved in the transcriptional regulation of dosage compensation in Drosophila. Mol Cell 21: 811-823, 2006.
20. Pfister S, Rea S, Taipale M, et al: The histone acetyltransferase hMOF is frequently downregulated in primary breast carcinoma and medulloblastoma and constitutes a biomarker for clinical outcome in medulloblastoma. Int J Cancer 122: 1207-1213, 2008.
21. Wang Y, Zhang R, Wu D, Lu Z, Sun W, Cai Y, Wang C and Jin J: Epigenetic change in kidney tumor: downregulation of histone acetyltransferase MYST1 in human renal cell carcinoma. J Exp Clin Cancer Res 32: 8, 2013.
22. Song JS, Chun SM, Lee JY, Kim DK, Kim YH and Jang SJ: The histone acetyltransferase hMOF is overexpressed in non-small cell lung carcinoma. Korean J Pathol 45: 386-396, 2011.
23. Zhao L, Wang DL, Liu Y, Chen S and Sun FL: Histone acetyltransferase hMOF promotes S phase entry and tumorigenesis in lung cancer. Cell Signal 25: 1689-1698, 2013.
24. Sameer AS: Colorectal cancer: molecular mutations and polymorphisms. Front Oncol 3: 114, 2013.
25. Jemal A, Siegel E, Ward E, Murray T, Xu J and Thun MJ: Cancer statistics. CA Cancer J Clin 57: 43-66, 2007.
26. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917, 2010.
27. Tamagawa H, Oshima T, Shiozawa M, et al: The global histone modification pattern correlates with overall survival in metachronous liver metastasis of colorectal cancer. Oncol Rep 27: 637-642, 2012.
28. Tamagawa H, Oshima T, Numata M, et al: Global histone modification of H3K27 correlates with the outcomes in patients with metachronous liver metastasis of colorectal cancer. EJSO 39: 655-661, 2013.
29. Liu N, Zhang R, Zhao X, et al: A potential diagnostic marker for ovarian cancer: involvement of the histone acetyltransferase, human males absent on the first. Oncol Lett 6: 393-400, 2013.
30. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL and Trotti A: AJCC Cancer Staging Manual. 7th edition. Springer, Chicago, IL, 2010.
31. Choschzick M, Oosterwijl R, Muller V, Woelber L, Simon R, Moch H and Tennstedt P: Overexpression of carbonic anhydrase IX (CAIX) is an independent unfavorable prognostic marker in endometrioid ovarian cancer. Virchows Arch 459: 193-200, 2011.
32. Liu X, Cao L, Ni J, et al: Differential BCCIP gene expression in primary human ovarian cancer, renal cell carcinoma and colorectal cancer tissues. Int J Oncol 43: 1925-1934, 2013.
33. Rea S, Xouri G and Akhtar A: Males absent on the first (MOF): from flies to humans. Oncogene 26: 5385-5394, 2007.
34. Taiple M, Rea S, Richter K, Vilar A, Lichter P, Imhof A and Akhtar A: hMOF histone acetyltransferase is required for histone H4 lysine 16 acetylation in mammalian cells. Mol Cell Biol 25: 6798-6810, 2005.